Danaher (DHR) concluded a turbulent trading week at $191.50, marking a 7.0% gain from Tuesday's close. Despite this rebound, the stock remains 6.0% below its level from the prior Friday, underscoring the lingering impact of the company's recent earnings disappointment.
The recovery recouped 56.5% of the $22.10 loss sustained on Tuesday, signaling that investors have taken some comfort in management's explanations for shipment delays. However, the deferral of over $100 million in bioprocessing revenue to 2027 represents a significant headwind that may cap further upside this year.
In contrast, Thermo Fisher Scientific (TMO) advanced 6.7% for the week after raising its full-year profit outlook, fueled by stronger demand across its business segments. A 12.8-point performance gap between the two companies suggests that Danaher's challenges are company-specific rather than indicative of a broader sector downturn. Thermo Fisher's robust results undermine arguments for a widespread decline in life sciences demand.
Danaher's July guidance reveals diverging trends. While core revenue growth expectations were trimmed—from 3%–6% in April to 3%–4% in July—adjusted earnings per share guidance was raised by 7.5 cents to a midpoint of $8.525. This earnings upgrade, however, is primarily attributed to the finalization of a recent acquisition rather than an acceleration of organic growth.
Second-quarter results showed revenue climbing 5.5% to $6.3 billion, with adjusted earnings per share advancing 8% to $1.94. Free cash flow remained robust, increasing 15.5% to $1.27 billion, which represents 145% of net income.
Segment performance was mixed. Biotechnology core sales grew 2.5%, falling short of the mid-single-digit target set in April. Life Sciences posted a 5.5% growth rate, its best performance in several years. Chief Executive Rainer Blair noted that bioprocessing orders "grew mid-teens in the quarter," but some major projects missed anticipated shipment timelines.
Chief Financial Officer Matt Gugino disclosed that over $100 million in revenue was deferred into 2027, with the majority of this delay impacting the second and third quarters. Looking ahead, Danaher forecasts core growth of 2% to 3% for the third quarter and aims for mid-single-digit growth in the fourth quarter.
Guggenheim analyst Subbu Nambi highlighted that investor focus will remain on bioprocessing growth and second-half guidance, placing order conversion as the next key evaluation point for the market. Next week, Avantor (AVTR) is set to report results before Wednesday's market open, with a conference call scheduled for 08:00 EDT. Danaher will pay its $0.40 quarterly dividend on Friday, July 31.
Key risks include extended project delays that could shift more sales into 2027, foreign exchange headwinds expected to reduce third-quarter revenue by roughly 1%, and execution challenges related to debt from acquisitions and integration processes. Friday's rebound offset some earlier losses but did not alter the fundamental outlook. A sustained recovery will require sales to align more closely with order momentum.
